Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Pathways and therapeutic targets in melanoma.

Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE.

Oncotarget. 2014 Apr 15;5(7):1701-52. Review.

2.

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.

Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, Yang PT, Chen HW, Haydu L, Toroni RA, Lucero OM, Chien AJ, Moon RT.

J Clin Invest. 2014 Jul;124(7):2877-90. doi: 10.1172/JCI70156. Epub 2014 May 27.

3.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS.

Nat Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712.

4.

New drug targets in metastatic melanoma.

Homet B, Ribas A.

J Pathol. 2014 Jan;232(2):134-41. doi: 10.1002/path.4259. Review.

PMID:
24027077
5.

Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.

Eberle J, Kurbanov BM, Hossini AM, Trefzer U, Fecker LF.

Drug Resist Updat. 2007 Dec;10(6):218-34. Epub 2007 Dec 3. Review.

PMID:
18054518
6.

[Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].

Capovilla M.

Ann Pathol. 2013 Dec;33(6):375-85. doi: 10.1016/j.annpat.2013.09.003. Epub 2013 Oct 31. Review. French.

PMID:
24331719
7.

Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.

Read J.

Australas J Dermatol. 2013 Aug;54(3):163-72. doi: 10.1111/ajd.12013. Epub 2013 Jan 18. Review.

PMID:
23330781
8.

The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.

Haluska F, Pemberton T, Ibrahim N, Kalinsky K.

Semin Oncol. 2007 Dec;34(6):546-54. Review.

PMID:
18083378
9.

Tyrosine kinases as targets for cancer therapy.

Krause DS, Van Etten RA.

N Engl J Med. 2005 Jul 14;353(2):172-87. Review. No abstract available.

10.

Genetic determinants of uveal melanoma.

Kaur J, Malik MA, Gulati R, Azad SV, Goswami S.

Tumour Biol. 2014 Dec;35(12):11711-7. doi: 10.1007/s13277-014-2681-7. Epub 2014 Oct 9. Review.

PMID:
25296731
11.

Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.

Dummer R, Flaherty KT.

Curr Opin Oncol. 2012 Mar;24(2):150-4. doi: 10.1097/CCO.0b013e32834fca92. Review.

PMID:
22316627
12.

Melanoma Treatments: Advances and Mechanisms.

Marzuka A, Huang L, Theodosakis N, Bosenberg M.

J Cell Physiol. 2015 Nov;230(11):2626-33. doi: 10.1002/jcp.25019. Review.

PMID:
25899612
13.

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.

Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, Shi W, Zhang Z, Rajasekhar VK, Pagano NC, Porco JA Jr, Teruya-Feldstein J, Rosen N, Zelenetz AD, Pelletier J, Wendel HG.

J Exp Med. 2011 Aug 29;208(9):1799-807. doi: 10.1084/jem.20110846. Epub 2011 Aug 22.

14.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

15.

Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.

Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ, Gandhi V.

Blood. 2012 Oct 25;120(17):3491-500. doi: 10.1182/blood-2012-02-412643. Epub 2012 Sep 6.

16.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, Midkiff BR, Liu J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK.

J Clin Invest. 2013 May;123(5):2257-67. doi: 10.1172/JCI67816. Epub 2013 Apr 15.

17.

BRAF, a target in melanoma: implications for solid tumor drug development.

Flaherty KT, McArthur G.

Cancer. 2010 Nov 1;116(21):4902-13. doi: 10.1002/cncr.25261. Review.

18.

Reactivation of p53 as therapeutic intervention for malignant melanoma.

Jochemsen AG.

Curr Opin Oncol. 2014 Jan;26(1):114-9. doi: 10.1097/CCO.0000000000000033. Review.

PMID:
24275854
19.

Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.

Dean E, Lorigan P.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1437-48. doi: 10.1586/era.12.124. Review.

PMID:
23249108
20.

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT.

Sci Signal. 2015 Aug 18;8(390):ra82. doi: 10.1126/scisignal.aab1111.

PMID:
26286024

Supplemental Content

Support Center